TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an announcement.
China Resources Pharmaceutical Group Ltd. has successfully completed the public issuance of the second tranche of its 2025 Corporate Bonds in the PRC, raising RMB1.1 billion. The proceeds will be utilized for various operational expenses, including debt repayment, working capital replenishment, and investments in scientific and technological innovations, which may strengthen the company’s financial position and support its growth initiatives.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is involved in scientific and technological innovations within the pharmaceutical sector.
Average Trading Volume: 15,447,347
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.97B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.